Smart Programmer Approved by FDA – Medtronic (MDT)

1
outside the Medtronics building

Medtronic plc (MDT) today announced U.S. Food and Drug Administration (FDA) approval of the InterStim(TM) smart programmer for use with the InterStim system, which provides sacral neuromodulation therapy for the treatment of overactive bladder (OAB), chronic fecal incontinence (FI) and non-obstructive urinary retention.

Linnea Burman, vice president:

“Medtronic pioneered sacral neuromodulation two decades ago and we continue to innovate to improve the patient and physician experience and make it easier for more patients to find effective relief from both OAB and FI with the InterStim system.”

The new smart programmer streamlines multiple devices into a single, intuitive, touch screen Samsung mobile device and enables clinicians to personalize each patient’s care and allows patients to manage their therapy simply and discreetly.

OAB and FI are treatable, extremely common and embarrassing conditions. More than 37 million adults in the United States – almost one in six – suffer from OAB and nearly 20 million Americans – about one in 12 – have bowel incontinence.1-4

“The advanced technology of the smart programmer paves the way for future digital health solutions, like digital symptom tracking, and should give physicians and patients confidence that relief and restored quality of life are possible.”

1 COMMENT

LEAVE A REPLY

Please enter your comment!
Please enter your name here